Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study


To cite this article: Elizabeth H. Phillips, Stephen Nash, Toyin Adedayo, Carol J. Whelan, Marianna Fontana, Shameem Mahmood, Helen J. Lachmann, Julian D. Gillmore, Paul Smith, Laura Clifton-Hadley, Philip N. Hawkins & Ashutosh D. Wechalekar (2017): Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study, Amyloid, DOI: 10.1080/13506129.2017.1385453

To link to this article: http://dx.doi.org/10.1080/13506129.2017.1385453

Published online: 06 Oct 2017.

Article views: 4

View related articles

View Crossmark data
LETTER TO THE EDITOR

Pitfalls in conducting prospective trials in stage III cardiac amyloidosis – experience from the REVEAL study

Very few prospective clinical trials have been conducted in advanced cardiac AL amyloidosis due to the rarity of the disease and challenging clinical course of the condition. With a median survival of only 7 months, cardiac AL represents a major area of unmet need [1]. The introduction of proteasome inhibitors and immunomodulatory agents over the last decade has marked a new era in the treatment of plasma cell dyscrasias. The phase 1 CAN2007 study demonstrated the feasibility of single-agent bortezomib in relapsed/refractory AL up to a dose of 1.3 mg/m² twice weekly [2]. The REsponse to VElace combination chemotherapy in AL amyloidosis (REVEAL) trial was conceived in 2008 to test the efficacy and toxicity of bortezomib-based triplet therapy in AL amyloidosis. Here, we report the course of the REVEAL trial, which illustrates the challenges in conducting trials where high mortality is part of the disease course.

REVEAL was designed as a parallel phase II trial assessing PAD (bortezomib, doxorubicin, dexamethasone) and CVD (cyclophosphamide, bortezomib, dexamethasone) for first-line treatment of stage II–III cardiac AL amyloidosis. Subcutaneous bortezomib 1 mg/m² and dexamethasone 20 mg were given on days 1, 4, 8 and 11 of a 21-day cycle. Bortezomib could be increased to 1.3 mg/m² if well tolerated and no evidence of early haematological response. Patients additionally received either weekly oral cyclophosphamide 350 mg/m² (CVD arm; maximum dose 500 mg) or intravenous doxorubicin 18 mg/m² (PAD arm, day 1 only). Each arm was independent to allow for separate stopping rules. Patients with NYHA stage IV heart failure or significant left ventricular systolic dysfunction were excluded.

The study opened to recruitment in March 2012. Three early deaths occurred in the first four patients recruited (2 PAD, 1 CVD arm), all attributed to sudden cardiac death and within 11 weeks of study entry (Table 1). The fourth patient (PAD arm) developed grade 4 corticosteroid-induced psychosis. All three deaths were assessed to be primarily amyloid-related. However, in the interest of patient safety, recruitment was halted to allow data to be reviewed by the independent data monitoring committee (IDMC).

There was prolonged dialogue between the IDMC, sponsors and drug manufacturers. The trial reopened after 11 months with a redesign including mandatory safety reporting to the IDMC after every three patients. Ventricular arrhythmia was added as an exclusion criterion and patients were required to undergo 24-h Holter monitoring prior to study entry. The chemotherapy protocol was changed to modified CVD (weekly bortezomib 1.3 mg/m² and dexamethasone 20 mg on days 1, 8, 15 and 22 of a 35-day cycle with cyclophosphamide on days 1 and 15) or VD alone. One further early patient death occurred in the next three patients recruited (CVD arm). Although this was within predefined limits for “expected outcome” for cardiac AL on this trial, as per protocol, recruitment was again suspended to allow data review by the IDMC.

Over the next 6 months, in discussion with the IDMC and sponsors, a number of further amendments were considered. At this juncture, bortezomib was available for frontline use and >200 patients had received upfront bortezomib [3], hence the impact on clinical practice of a small prospective study was felt to be limited. In the light of published experience with use of CVD [4], we proposed closing the CVD arm and changing the VD arm to single-agent escalating dose bortezomib. The ethics committee accepted these modifications but the UK regulatory authority (MHRA) deemed this a substantial amendment to trial design requiring full regulatory resubmission. The study was therefore formally closed in late 2014.

Baseline characteristics, treatment and responses for the seven patients recruited are detailed in Table 1. Median age at enrolment was 57 years (range 34–68). Three patients (43%) had high-risk stage IIIb cardiac disease, defined by N-terminal pro B-natriuretic peptide >8500 ng/l and/or systolic BP <100 mmHg [1], of which two died. The median number of treatment cycles delivered was three (<1–6 cycles). All four deaths (57%) were attributed to sudden cardiac death/arrhythmia. Four patients (57%) achieved at least very good partial haematological response within 1–3 cycles. The overall survival curve is shown in Figure 1. No relapses or deaths occurred in the three patients who completed treatment with 12.1 to 31.7-month follow-up.

Cardiac AL amyloidosis is known to have an early mortality of 23–42% [1,5]. Given the small number of patients recruited to this study, it is unclear whether the early mortality was purely disease-related or whether the drugs (bortezomib or any of the other agents) had an additional role. Of note, doxorubicin at a higher dose of 36 mg/m² has been administered as part of both VAD in AL amyloidosis and PAD in myeloma without excess cardiotoxicity [6,7].

It had been hoped that bortezomib might radically impact survival in cardiac AL amyloidosis, after the rapid responses seen in early studies. The experience from this study prompted detailed retrospective data review from UK, Italy and Germany resulting in three seminal publications comparing CDT with CVD [4], Mel-Dex with VMelDex [8]...
and a reassessment of cardiac staging in AL amyloidosis, subdividing advanced cardiac AL amyloidosis into stage IIIa and stage IIIb disease [1]. Patients with stage IIIb disease are now recognized to have a median survival of 3 months [1]. Chemotherapy has not been demonstrated to improve outcomes for the majority of these patients, apart from a very small proportion who obtain deep haematological remissions [3]. Stage IIIb cardiac AL amyloidosis is now considered a standard exclusion criteria in upfront AL amyloidosis trials [9].

A number of novel amyloid-specific treatments are in development, including drugs that accelerate amyloid fibril removal [10]. It is now essential that prospective trials are rationally conducted in cardiac AL amyloidosis including patients at high risk of death. Building safeguards at each level is essential. However, this study showed that it is crucial for the IDMC, sponsors, regulators and funders to understand the complexity of AL amyloidosis. This will allow for understanding of the “expectedness” of events, including a very high incidence of early deaths, to avoid the pitfalls that led to prolonged delays at every stage and eventual closure of this trial. Although this study closed prematurely, it has provided valuable lessons, prompted retrospective studies that have immensely increased our understanding of AL amyloidosis and generated a new staging system and criteria which have now been adopted for trial entry.

Table 1. Individual patient characteristics.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>WHO PS</th>
<th>Mayo stage</th>
<th>NYHA class</th>
<th>NT-proBNP (ng/l)</th>
<th>Troponin T (µg/l)</th>
<th>dFLC (mg/l)</th>
<th>Systolic BP</th>
<th>Other organ involvement</th>
<th>Treatment</th>
<th>Number of cycles</th>
<th>Best haematological response</th>
<th>Survival (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>57</td>
<td>0</td>
<td>II</td>
<td>I</td>
<td>1144</td>
<td>0.05</td>
<td>1124</td>
<td>101</td>
<td>nil</td>
<td>PAD</td>
<td>3</td>
<td>CR</td>
<td>2.5</td>
</tr>
<tr>
<td>2</td>
<td>57</td>
<td>1</td>
<td>III</td>
<td>II</td>
<td>12025</td>
<td>0.06</td>
<td>408</td>
<td>124</td>
<td>Skin</td>
<td>PAD</td>
<td>1</td>
<td>SD</td>
<td>&gt;31.7</td>
</tr>
<tr>
<td>3</td>
<td>64</td>
<td>2</td>
<td>II</td>
<td>I</td>
<td>415</td>
<td>0.03</td>
<td>572</td>
<td>95</td>
<td>Renal</td>
<td>PAD</td>
<td>3</td>
<td>CR</td>
<td>&gt;14.8</td>
</tr>
<tr>
<td>4</td>
<td>59</td>
<td>1</td>
<td>III</td>
<td>II</td>
<td>2500</td>
<td>0.12</td>
<td>962</td>
<td>135</td>
<td>nil</td>
<td>CVD⁴</td>
<td>2</td>
<td>SD</td>
<td>&gt;1.2</td>
</tr>
<tr>
<td>5</td>
<td>47</td>
<td>2</td>
<td>III</td>
<td>II</td>
<td>11229</td>
<td>0.13</td>
<td>247</td>
<td>108</td>
<td>Renal</td>
<td>CVD³</td>
<td>6</td>
<td>VGPR</td>
<td>&gt;14.8</td>
</tr>
<tr>
<td>6</td>
<td>34</td>
<td>3</td>
<td>III</td>
<td>III</td>
<td>10186</td>
<td>nk</td>
<td>2417</td>
<td>80</td>
<td>Renal</td>
<td>CVD³</td>
<td>&lt;1</td>
<td>n/a</td>
<td>0.3</td>
</tr>
<tr>
<td>7</td>
<td>68</td>
<td>1</td>
<td>III</td>
<td>II</td>
<td>441</td>
<td>0.03</td>
<td>111</td>
<td>116</td>
<td>Renal</td>
<td>VD</td>
<td>5</td>
<td>VGPR</td>
<td>&gt;12.1</td>
</tr>
</tbody>
</table>

⁴CVD 21-day cycle. ⁵CVD 35-day cycle.


Disclosure statement

AW has received honoraria from Janssen-Cilag. All other authors report no conflicts of interest.

Funding

This trial was funded by Cancer Research UK (reference C23725/A11440) and registered at EudraCT (reference 2009–014906-33). Bortezomib was supplied free of charge by Janssen-Cilag.

References

Elizabeth H. Phillips, Stephen Nash and Toyin Adedayo
Cancer Research UK and University College London Cancer Trials Centre, University College London, London, UK

Carol J. Whelan, Marianna Fontana, Shameem Mahmood, Helen J. Lachmann and Julian D. Gillmore
National Amyloidosis Centre, University College London, London, UK

Paul Smith and Laura Clifton-Hadley
Cancer Research UK and University College London Cancer Trials Centre, University College London, London, UK

Philip N. Hawkins and Ashutosh D. Wechalekar
National Amyloidosis Centre, University College London, London, UK

Received 27 July 2017; revised 25 September 2017; accepted 25 September 2017

© 2017 Informa UK Limited, trading as Taylor & Francis Group